Louisiana 2014 Regular Session

Louisiana House Bill HB157

Introduced
3/10/14  
Introduced
3/10/14  
Refer
3/10/14  

Caption

Requires all newborns to be screened for adrenoleukodystrophy

Impact

By incorporating ALD into the standard newborn screening panel, HB 157 aims to align state health policies with best practices in pediatric care. This legislative change is expected to lead to an increase in awareness and testing for ALD among healthcare providers. The bill retains the provision that parents can opt out of the screening for personal or religious reasons, reflecting a balance between public health initiatives and parental rights. Therefore, while the coverage expands, so too does the public health infrastructure's responsibility to inform and educate families about the benefits of testing for ALD.

Summary

House Bill 157 seeks to enhance the early detection of genetic disorders by mandating that all newborns be screened for adrenoleukodystrophy (ALD). This is an addition to the existing requirements for newborn screenings, which already include a range of genetic conditions like phenylketonuria and congenital hypothyroidism. The bill is rooted in the understanding that early diagnosis of ALD can significantly impact treatment options and improve health outcomes in affected infants, making timely detection crucial for effective management of the condition.

Sentiment

Overall, the sentiment surrounding HB 157 is positive among child health advocates and medical professionals who recognize the importance of early intervention in genetic disorders. Supporters argue that including ALD in newborn screens can facilitate better health monitoring and potentially save lives. There appears to be broad consensus among pediatricians that early screening is beneficial, although some discussions may revolve around the implications of increasing the number of tests and the potential burden it could place on families who may opt for extensive testing.

Contention

While the bill enjoys considerable support, there remains a nuance of contention regarding parental rights and responsibilities. Some critics express concern over the government imposing additional mandatory screenings without fully addressing parental autonomy in healthcare decisions. The complexity of genetic testing decisions can weigh heavily on parents, especially those already facing challenging circumstances with healthcare access. Nevertheless, the overall legislative intent of HB 157 aims to prioritize the health and safety of newborns while ensuring parental rights remain respected.

Companion Bills

No companion bills found.

Similar Bills

LA HB283

Requires screening of newborns for Krabbe disease (EN +$798,907 GF EX See Note)

LA HB316

Adds mucopolysaccharidosis type I and glycogen storage disorder type II to the state's newborn screening panel (EN +$187,717 GF EX See Note)

LA HB122

Provides relative to the mandatory screening of all newborns for early detection of the cytomegalovirus (CMV) (OR NO IMPACT See Note)

CA AB2735

Genetically Handicapped Persons Program.

LA HB291

Adds mucopolysaccharidosis type I and glycogen storage disorder type II to the state's newborn screening panel

LA HB200

Provides relative to newborn screening for certain genetic conditions (EN SEE FISC NOTE GF EX See Note)

KY HB374

AN ACT relating to newborn and infant screenings.

KY SB105

AN ACT relating to newborn and infant screenings.